Drugs / AAV1/SERCA2a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01643330 | Jul 2012 → Feb 2015 | cardiomyopathy, heart failure | Celladon Corporation | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00534703 Comparator | Jul 2014 → Sep 2015 | left ventricular failure | Imperial College London | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV1/SERCA2a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01643330 ↗ |
| Known as | MYDICAR | “AAV1/SERCA2a (MYDICAR)” NCT01643330 ↗ |
| Action | Restore | “restoration of SERCA2a levels can improve function to near normal levels” NCT00534703 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “giving an adeno-associated viral vector expressing the sarcoplasmic reticulum calcium ATPase (SERCA2a)” NCT00534703 ↗ |
| Route | Other | “The vector will be delivered during a cardiac catheterisation procedure by a 10-minute infusion into the coronary arteries.” NCT00534703 ↗ |